Treatment of Frontotemporal Dementia (original) (raw)

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Seltman R, Matthews B. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drugs. 2012;26:841–70. Excellent review article of FTLD syndromes.
    Article PubMed CAS Google Scholar
  2. Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioral variant of frontotemporal dementia. Brain. 2011;134:2456–77.
    Article PubMed PubMed Central Google Scholar
  3. Gorno-Tempini ML, HIllis A, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–14.
    Article PubMed PubMed Central Google Scholar
  4. Armstrong M, Litvan I, Lang A, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80:496–503.
    Article PubMed PubMed Central Google Scholar
  5. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszeweski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47:1–9.
    Article PubMed CAS Google Scholar
  6. Dickson DW, Ahmed Z, Algom AA, et al. Neuropathology of variants of progressive supranuclear palsy. Curr Opin Neurol. 2010;23:394–400.
    Article PubMed Google Scholar
  7. Brooks B, Miller R, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
    Article PubMed CAS Google Scholar
  8. Ringholz G, Appel S, Bradshaw M, et al. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005;65:586.
    Article PubMed CAS Google Scholar
  9. Mackenzie IR, Neumann M, Bigio EH, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119:1–4.
    Article PubMed PubMed Central Google Scholar
  10. Fratiglioni L, Paillard-Borg S, Winblad B. An active and socially integrated lifestyle in late life might protect against dementia. Lancet Neurol. 2004;3:343.
    Article PubMed Google Scholar
  11. US National Institute of Health Clinical Trials Registry 2013. Available at http://clinicaltrials.gov/show/NCT00382824. Accessed 23 Jul 2014.
  12. Moretti R, Torre P, Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004;21:93107.
    Article Google Scholar
  13. Kertesz A, Morlog D, Light M, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dement Geriatr Cogn Disord. 2008;25:178–85.
    Article PubMed CAS Google Scholar
  14. Mendez MF, Shapira JS, McMurtray A, et al. Preliminary findings: behavioral worsening on donepezil in patients with frontotemporal dementia. Am J Geriatr Psychiatr. 2007;15:84–7.
    Article Google Scholar
  15. Kimura T, Takamatsu J. Pilot study of pharmacological treatment for frontotemporal dementia: risk of donepezil treatment for behavioral and psychological symptoms. Geriatr Gerontol Int. 2013;13:506–7.
    Article PubMed Google Scholar
  16. Litvan I, Gomez C, Atack JR, et al. Physostigmine treatment of progressive supranuclear palsy. Ann Neurol. 1989;26(3):404–7.
    Article PubMed CAS Google Scholar
  17. Fabbrini G, Barbanti P, Bonifati V, et al. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand. 2001;103(2):123–5.
    Article PubMed CAS Google Scholar
  18. Litvan I, Phipps M, Pharr VL, et al. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001;57(3):467–73.
    Article PubMed CAS Google Scholar
  19. Liepelt I, Gaenslen A, Godau J, et al. Rivastigmine for the treatment of dementia in patients with progressive supranuclear palsy: clinical observations as a basis for power calculations and safety analysis. Alzheimers Dement. 2010;6(1):70–4.
    Article PubMed CAS Google Scholar
  20. Diehl-Schmid J, Förstl H, Perneczky R, et al. A 6-month, open-label study of memantine in patients with frontotemporal dementia. Int J Geriatr Psychiatr. 2008;23:754–9.
    Article Google Scholar
  21. Swanberg MM. Memantine for behavioral disturbances in frontotemporal dementia: a case series. Alzheimer Dis Assoc Disord. 2007;21:164–6.
    Article PubMed Google Scholar
  22. Boxer AL, Lipton AM, Womack K, et al. An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord. 2009;23:211–7.
    Article PubMed CAS PubMed Central Google Scholar
  23. Vercelletto M, Boutoleau-Bretonnière C, Volteau C, et al. Memantine in behavioral variant frontotemporal dementia: negative results. J Alzheimer Dis. 2011;23:749–59. First large randomized, double-blind, controlled trial of memantine in FTD patients that did not reach primary endpoints.
    Google Scholar
  24. Boxer AL, Knopman DS, Kaufer DI, et al. Memantine in patients with frontotemporal lobar degeneration: a multicenter, randomized, double-blind, placebo-controlled trial. Lancet Neurol. 2013;12:149–56. Large multi-center, randomized, double-blind, controlled therapeutic trial demonstrating memantine lack of efficacy.
    Article PubMed CAS PubMed Central Google Scholar
  25. Hermann N, Black SE, Chow T, et al. Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. Am J Geriatr Psychiatr. 2012;20:789–97.
    Article Google Scholar
  26. Swartz JR, Miller BL, Lesser IM, et al. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry. 1997;58:212–6.
    Article PubMed CAS Google Scholar
  27. Mendez MF, Shapira JS, Miller BL. Stereotypical movements and frontotemporal dementia. Mov Disord. 2005;20:742–5.
    Article PubMed Google Scholar
  28. Anneser JM, Jox RJ, Borasio GD. Inappropriate sexual behavior in a case of ALS and FTD: successful treatment with sertraline. Amyotroph Lateral Scler. 2007;8:189–90.
    Article PubMed CAS Google Scholar
  29. Prodan CI, Monnon M, Ross ED. Behavioral abnormalities associated with rapid deterioration of language functions in semantic dementia respond to sertraline. J Neurol Neurosurg Psychiatry. 2009;80:1416–7.
    Article PubMed CAS Google Scholar
  30. Chow TW, Mendez MF. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen. 2002;17:267–72.
    Article PubMed Google Scholar
  31. Moretti R, Torre P, Antonello RM, et al. Frontotemporal dementia: paroxetine as a possible treatment of behavioral symptoms. A randomized, controlled, open 14-month study. Eur Neurol. 2003;49:13–9.
    Article PubMed CAS Google Scholar
  32. Deakin JB, Rahman S, Nestor PJ, et al. Paroxetine does not improve symptoms and impairs cognitive in frontotemporal dementia: a double-blind randomized controlled trial. Psychopharamcology (Berl). 2004;172:400–8.
    Article CAS Google Scholar
  33. Lebert F, Stekke W, Hasenbroekx C, et al. Frontotemoporal dementia: a randomized, controlled trial with trazodone. Dement Geriatr Cogn Disord. 2004;17:355–9.
    Article PubMed CAS Google Scholar
  34. Curtis RC, Resch DS. Case of pick’s central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J Clin Psychopharmacol. 2000;20:384–5.
    Article PubMed CAS Google Scholar
  35. Fellgiebel A, Müller MJ, Hiemke C, et al. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry. 2007;8:123–6.
    Article PubMed Google Scholar
  36. Reeves RR, Perry CL. Aripiprazole for sexually inappropriate vocalizations in frontotemporal dementia. J Clin Psychopharmacol. 2013;33:145–6.
    Article PubMed Google Scholar
  37. Moretti R, Torre P, Antonello RM, et al. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer’s disease and other dementias: a 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen. 2003;18:205–14.
    Article PubMed Google Scholar
  38. Huey ED, Garcia C, Wassermann EM, et al. Stimulant treatment of frontotemporal dementia in 8 patients. J Clin Psychiatry. 2008;69:1981–2.
    Article PubMed Google Scholar
  39. Pijnenburg YA, Sampson EL, Harvey RJ, et al. Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatr. 2003;18:67–72.
    Article CAS Google Scholar
  40. Asmal L, Flegar SJ, Wang J, et al. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2013;11: CD006625. doi:10.1002/14651858.CD006625.pub3. Meta-Analysis of side effect and efficacy profile of many antipsychotics.
    PubMed Google Scholar
  41. Mioshi E, Foxe D, Leslie F, et al. The impact of dementia severity on caregiver burden in frontotemporal dementia and Alzheimer disease. Alzheimer Dis Assoc Disord. 2013;27:68–73.
    Article PubMed Google Scholar
  42. Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology. 2006;66:17–22.
    Article PubMed CAS Google Scholar
  43. Rahman S, Robbins TW, Hodges JR, et al. Methylphenidate (‘Ritalin’) can ameliorate abnormal risk-taking behavior in the frontal variant of frontotemporal dementia. Neuropsychopharmacology. 2006;31:651–8.
    Article PubMed CAS PubMed Central Google Scholar
  44. Poetter CE, Stewart JT. Treatment of indiscriminate, inappropriate sexual behavior in frontotemporal dementia with carbamazepine. J Clin Psychopharmacol. 2012;31:137–8.
    Article Google Scholar
  45. Fleisher A, Truran D, Mai J, et al. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology. 2011;77:1263–71.
    Article PubMed CAS PubMed Central Google Scholar
  46. Cruz M, Marinho V, Fontenelle LF, et al. Topiramate may modulate alcohol abuse but not other compulsive behaviors in frontotemporal dementia: case report. Cogn Behav Neurol. 2008;21:104–6.
    Article PubMed Google Scholar
  47. Nestor PJ. Reversal of abnormal eating and drinking behavior in a frontotemporal lobar degeneration patient using low-dose topiramate. J Neurol Neurosurg Psychiatry. 2012;83:349–50.
    Article PubMed Google Scholar
  48. Singam C, Walterfang M, Mocellin R, et al. Topiramate for abnormal eating behavior in frontotemporal dementia. Behav Neurol. 2013;27:285–6.
    Article PubMed Google Scholar
  49. Shinagawa S, Tsuno N, Nakayama K. Managing abnormal eating behaviors in frontotemporal lobar degeneration in patients with topiramate. Psychogeriatrics. 2013;13:58–61.
    Article PubMed Google Scholar
  50. Jesso S, Morlog D, Ross S, et al. The effects of oxytocin on social cognition and behavior in frontotemporal dementia. Brain. 2011;134:2493–501.
    Article PubMed Google Scholar
  51. Sha SJ, Boxer A. Treatment implications of C9ORF72. Alzheiemers Res Ther. 2012;4:46.
    Article CAS Google Scholar
  52. Boxer AL, Mackenzie IR, Boeve BF, et al. Clinical, neuroimaging and neuropatholgoical featuers of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry. 2011;82:196–203.
    Article PubMed PubMed Central Google Scholar
  53. DeJesus-Hernandez M, Mackenzie IR, et al. Expanded GGGC CC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245–56.
  54. Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257–68.
    Article PubMed CAS PubMed Central Google Scholar
  55. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330:585–91.
    Article PubMed CAS Google Scholar
  56. Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425–31.
    Article PubMed CAS Google Scholar
  57. Klawans Jr HL, Ringel SP. Observations on the efficacy of L-dopa in progressive supranuclear palsy. Eur Neurol. 1971;5(2):115–29.
    Article PubMed Google Scholar
  58. Kompoliti K, Goetz CG, Litvan I, et al. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol. 1998;55(8):1099–102.
    Article PubMed CAS Google Scholar
  59. Birdi S, Rajput AH, Fenton M, et al. Progressive supranuclear palsy diagnosis and confounding features: report on 16 autopsied cases. Mov Disord. 2002;17(6):1255–64.
    Article PubMed Google Scholar
  60. Kortte K, Rogalski E. Behavioural interventions for enhancing life participation in behavioral variant frontotemporal dementia and primary progressive aphasia. Int Rev Psychiatr. 2013;25:237–45. Review of non-pharmacological interventions for FTD patients.
    Article Google Scholar
  61. US National Institute of Health Clinical Trials Registry 2013. Available at http://clinicaltrials.gov/show/NCT01835665. Accessed 22 Aug 2014.
  62. US National Institute of Health Clinical Trials Registry 2013. Available at http://www.clinicaltrials.gov/ct2/show/NCT02149160. Accessed 22 Aug 2014.
  63. US National Institute of Health Clinical Trials Registry 2013. Available at http://clinicaltrials.gov/ct2/show/NCT01626378. Accessed 23 Jul 2014.
  64. Höglinger GU, Huppertz HJ, Wagenpfeil S, TAUROS MRI Investigators, et al. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial. Mov Disord. 2014;29(4):479–87.
    Article PubMed Google Scholar
  65. Tolosa E, Litvan I, Höglinger GU, TAUROS Investigators, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014;29(4):470–8.
    Article PubMed CAS Google Scholar
  66. Yanamandra K, Kfoury N, Jiang H, et al. Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron. 2013;80(2):402–14.
    Article PubMed CAS Google Scholar
  67. Boxer A, Lang A, Grossman M, AL-108-231 investigators. Davunetide in patients with progressive supranuclear palsy: a randomized, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014;13:676–85. Largest clinical trial of PSP to date.
    Article PubMed CAS Google Scholar
  68. US National Institute of Health Clinical Trials Registry 2013. Available at http://clinicaltrials.gov/ct2/show/NCT02133846. Accessed 23 Jul 2014.
  69. Donnelly CJ, Zhang PW, Pham JT, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415–28.
    Article PubMed CAS PubMed Central Google Scholar
  70. Su Z, Zhang Y, Gendron TF, et al. Discovery of a biomarker and lead small molecules to target r(GGGG CC)-associated defects in c9FTD/ALS. Neuron. 2014. doi:10.1016/j.neuron.2014.07.041.

Download references